CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer

Clinical Cancer Research

Volumn 13, Issue 23, 2007, Pages 6947-6958

  Kiniwa, Yukiko ^a   Miyahara, Yoshihiro ^a   Wang, Helen Y ^a   Peng, Weiyi ^a   Peng, Guangyong ^a   Wheeler, Thomas M ^b   Thompson, Timothy C ^b   Old, Lloyd J ^c   Wang, Rong Fu ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR 8; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CONTACT; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOSUPPRESSION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 8;

EID: 37249067503     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0842     Document Type: Article

References (47)

1. Wang RF. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol Rev 2002;188:65-80.
2. Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12:1260-9.
3. McNeel DG, Malkovsky M. Immune-based therapies for prostate cancer. Immunol Lett 2005;96:3-9.
4. Slovin SF. Emerging role of immunotherapy in the management of prostate cancer. Oncology (Huntingt) 2007;21:326-33; discussion 34, 38, 46-8.
5. Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Oncol Rep 2007;9:226-33.
6. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
7. + regulatory T cells and their ligands: implication for immunotherapy. Immunity 2004;20:107-18.
8. + regulatory T cells. J Immunol 2005;174:2661-70.
9. Baecher-Allan C, Anderson DE. Immune regulation in tumor-bearing hosts. Curr Opin Immunol 2006;18:214-9.
10. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) Tcells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72.
11. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
12. Wang RF, Peng G, Wang HY. Regulatory T cells and Toll-like receptors in tumor immunity. Semin Immunol 2006;18:136-42.
13. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a) monoclonal antibody. Cancer Res 1999;59:3128-33.
14. + regulatory T cell function. Science 2005;309:1380-4.
15. high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398-405.
16. + suppressor T cells. J Clin Invest 2004;114:1218-21.
17. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intra-tumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
18. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
19. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
20. Tien AH, Xu L, Helgason CD. Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res 2005;65:2947-55.
21. Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 2004;114:1198-208.
22. Vlad G, Cortesini R, Suciu-Foca N. License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J Immunol 2005;174:5907-14.
23. + T cells restricted by the MHC class Ib molecule, Qa-1. Annu Rev Immunol 2000;18:185-216.
24. + regulatory T cells in the maintenance of T cell homeostasis. J Exp Med 2004;200:1123-34.
25. + regulatory thymocytes. Blood 2003;102:4107-14.
26. + T cells with a regulatory phenotype and function. Eur J Immunol 2005;35:2896-908.
27. + T lymphocytes from MHC class II-deficient mice exhibit regulatory activity. J Immunol 2005;175:246-53.
28. + regulatory T cells in human ovarian carcinoma. Cancer Res 2005;65:5020-6.
29. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor foxp3. Science 2003;299:1057-61.
30. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4(+)CD25(+) regulatory T cells. Nat Immunol 2003;4:330-6.
31. Fontenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005;22:329-41.
32. + Tregulatory cells in humans. Hum Immunol 2005;66:13-20.
33. + regulatory T cells at the single-cell level. Eur J Immunol 2005;35:1681-91.
34. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006;24:209-26.
35. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62.
36. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
37. Greten FR, Eckmann L, Greten TF, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
38. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-59.
39. Palapattu GS, Sutcliffe S, Bastian PJ, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005;26:1170-81.
40. Sugar LM. Inflammation and prostate cancer. Can J Urol 2006;13 Suppl 1:46-7.
41. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006;66:1123-31.
42. Wang RF. Functional control of regulatory T cells and cancer immunotherapy. Semin Cancer Biol 2006;16:106-14.
43. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33.
44. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005;28:582-92.
45. Jurk M, Heil F, Vollmer J, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002;3:499.
46. Sutmuller RP, den Brok MH, Kramer M, et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006;116:485-94.
47. + regulatory T cells. Proc Natl Acad Sci U S A 2006;103:7048-53.